This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Mizuho Securities Sticks to Their Buy Rating for Healthpeak Properties (DOC)

Tipranks - Tipranks - Tue Jul 7, 7:34AM CDT

In a report released today, Vikram Malhotra from Mizuho Securities maintained a Buy rating on Healthpeak Properties, with a price target of $24.00.

4th of July Sale - 70% Off

Malhotra covers the Real Estate sector, focusing on stocks such as Equinix, Healthpeak Properties, and Rexford Industrial Realty. According to TipRanks, Malhotra has an average return of 1.9% and a 51.60% success rate on recommended stocks.

Currently, the analyst consensus on Healthpeak Properties is a Moderate Buy with an average price target of $21.50.

See Insiders’ Hot Stocks on TipRanks >>

Based on Healthpeak Properties’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $752.95 million and a net profit of $193.63 million. In comparison, last year the company earned a revenue of $702.89 million and had a net profit of $42.83 million

Based on the recent corporate insider activity of 45 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of DOC in relation to earlier this year. Most recently, in May 2026, Scott R Bohn, the CDO and Head of Lab of DOC sold 10,989.00 shares for a total of $213,736.05.

Read More on DOC:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).